Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-07-27
Based on 659 first isolates · URO · Cystitis (lower UTI) · 2024-07-28 → 2025-07-27
Urology
Per-organism detail: URO urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 84 % (81 %–87 %)
No tissue or blood levels: cystitis only.
Not covered: Klebsiella pneumoniae (5 %), Proteus mirabilis (5 %), Pseudomonas aeruginosa (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
85 %
84 %
n = 56
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
84 %
84 %
n = 56
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
80 %
80 %
n = 56
mecillinam MEC
trend · Escherichia coli lower UTI only
77 %
75 %
n = 56
ciprofloxacin CIP
trend · Escherichia coli
74 %
70 %
n = 56
ceftriaxone CRO
trend · Escherichia coli
73 %
64 %
n = 56
66 %
59 %
n = 56
trimethoprim TMP
trend · Escherichia coli lower UTI only
65 %
55 %
n = 56
46 %
38 %
n = 56
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
16 %
n = 56
4 %
7 %
n = 56
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
2 %
n = 56

Most likely organisms for this profile

Escherichia coli
58 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
10 %
Proteus mirabilis
5 %
Pseudomonas aeruginosa
4 %
Staphylococcus aureus
3 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.